


Amendment to the Claims

Please amend Claims 1, 5, 12, and 24 as follow:

1. (Currently amended) A compound selected from the group consisting of the formula:




wherein  $R_1$  is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons; and

$R_2$  is an aliphatic chain having ~~2 to 18~~ 6, 7 and 8 carbons;

$R_3$  is a tertiary amine; and

$R_4$  is a group that is selectively hydrolyzed in a target cell.


2. (Original) The compound of Claim 1 where  $R_3$  is pyrrolidino.
3. (Original) The compound of Claim 1 wherein  $R_4$  is selected from the group consisting of an acetyl,  $-\text{CO}(\text{CH}_2)_n\text{CH}_3$  wherein  $n$  is at least 1 and



and wherein  $R_5$  is an alkyl group.

4. (Original) The compound of Claim 1 where  $R_1$  is 4-hydrophenyl.
5. (Presently amended) The compound of Claim 1 where  $R_1$  is ~~3,4-ethylenedioxy~~ 3',4'-ethylenedioxy-1-phenyl.

6. (Original) A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.
7. (Original) A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.
8. (Original) A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.
9. (Original) A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.
10. (Original) A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.
11. (Original) A vaccination method comprising the steps of:
  - a) removing cancer cells sensitive to the compounds below from a patient:
  - b) treating the cancer cells in vitro with an effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.
12. (Currently amended) A compound selected from the group consisting of the formula:



wherein ~~R<sub>1</sub> is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons; and~~


R<sub>2</sub> is an aliphatic chain having ~~2 to 18~~ 6, 7 and 8 carbons;

R<sub>3</sub> is a tertiary amine;

R<sub>4</sub> is a group that is selectively hydrolyzed in a target cell or a hydrogen; and


R<sub>6</sub> is a group that is selectively hydrolyzed in a target cell.

13. (Original) The compound of Claim 12 wherein R<sub>3</sub> is pyrrolidino.
14. (Original) The compound of Claim 12 wherein R<sub>4</sub> is selected from the group consisting of an acetyl, -CO(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub> wherein n is at least 1 and



and wherein R<sub>5</sub> is an alkyl group.


15. (Original) The compound of Claim 12 wherein R<sub>6</sub> is selected from the group consisting of an acetyl, -CO(CH<sub>2</sub>)<sub>n</sub>CH<sub>3</sub> wherein n is at least 1 and



and wherein R<sub>5</sub> is an alkyl group.

16. (Original) The compound of Claim 12 wherein R<sub>1</sub> is 4-hydroxyphenal.
17. (Original) The compound of Claim 12 wherein R<sub>1</sub> is 3,4-ethylenedioxy.
18. (Original) A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.
19. (Original) A method for treating a patient having sphingolipidosis by reducing glycosphingolipid syntheses comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.
20. (Original) A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.
21. (Original) A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.

22. (Original) A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.
23. (Original) A vaccination method comprising the steps of:
- removing cancer cells sensitive to the compounds below from a patient;
  - treating the cancer cells in vitro with an effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.
24. (Currently amended) A compound selected from the group of the formulas:



wherein  $\text{R}_2$  is an aliphatic chain having 2 to 18 6, 7 and 8 carbons;  
 $n$  is an integer from 1 to 19; and  
 $\text{R}_3$  is a tertiary amine.

25. (Original) The compound of Claim 24 wherein  $\text{R}_3$  is pyrrolidino.

26. (Original) A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.
27. (Original) A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.
28. (Original) A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.
29. (Original) A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.
30. (Original) A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.
31. (Original) A vaccination method comprising the steps of:
  - a) removing cancer cells sensitive to the compounds below from a patient;
  - b) treating the cancer cells in vitro with an effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.